Deltagen’s unique systems biology approach is designed to help clear the first and major hurdle of drug target discovery: lead validation. Our high-throughput in vivo mammalian knockout technology enables us to identify and validate the utility of genomic targets within a living model at an extraordinary scale and speed. Using our proprietary tools, we believe we can uncover clinically relevant drug targets more efficiently and earlier in the discovery process.

Novel Drug Targets—Expertise and Experience

The scientists in our Target Discovery Program have developed methods to discover the gene function of novel drug targets and to understand disease pathways as we strive to accelerate the development of meaningful, commercially promising small-molecule and secreted-protein therapies. Our proprietary technology platforms serve the drug discovery efforts of our pharmaceutical partners and customers.